HLX 31
Alternative Names: HLX 31Latest Information Update: 20 Feb 2023
At a glance
- Originator Henlix Biotech
- Class Bispecific antibodies
- Mechanism of Action CD3 antigen modulators; Epidermal growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Gastric cancer
Most Recent Events
- 08 Feb 2023 Discontinued for Breast cancer in Taiwan (Parenteral) (Shanghai Henlius Biotech pipeline, February 2023)
- 08 Feb 2023 Discontinued for Gastric cancer in Taiwan (Parenteral) (Shanghai Henlius Biotech pipeline, February 2023)
- 28 Jun 2022 No recent reports of development identified for research development in Breast-cancer in Taiwan (Parenteral)